KLRK1 and neoplasm: DNA transposons have emerged as promising non-viral vectors for immunotherapeutic applications, particularly in gene therapy applications of CAR T. In our study, we successfully constructed a CAR T system with hyMG and observed that a single infusion of NKG2D CAR T cells for tumor treatment in HCT116 intestinal cancer-bearing mice and inhibited tumor progression after 28 days (Figure 6).